October 13, 2025 /
Andreas Muehler, MD, chief medical officer at Immunic Therapeutics, discusses vidofludimus calcium, an experimental therapy for the treatment of relapsing and progressive forms of multiple sclerosis (MS). Muehler reflects on treatment needs across MS populations, including patient priorities, safety concerns, and the importance of therapies that balance efficacy with tolerability.
For more from Andreas Muehler, read our article here.
Transcript
I think from our point of view, there are multiple populations and subpopulations of MS where this drug will fit very well what patients need.
———————
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY
